Lantheus price target raised to $128 from $114 at JonesResearch

JonesResearch raised the firm’s price target on Lantheus to $128 from $114 and keeps a Buy rating on the shares. The company continued its solid commercial execution in Q4 and the market underappreciates its opportunities for expansion, the analyst tells investors in a research note. The firm believes the market is overly focused on Lantheus’ near-term quarterly results and not focused enough on broader industry trends and pipeline potential. It thinks the company will be successful in its efforts to dramatically expand both its therapeutic and imaging radiopharmaceutical product lines within the next two to five years.